History of international ethics and gene therapy varies from country to country
Gene therapy is a significant development in the history of medicine on three fronts. Firstly, the extent of public debate of the ethics of gene therapy both before and after the first trials is unique. Secondly, the breadth of its potential to combat genetic disorders as well as advanced acquired conditions such as heart disease and cancers that are beyond conventional cure is unparalleled. Thirdly, it has the potential to affect germline cells.
The first gene therapy trials arrived in the clinic at a time when the gradual shift towards patient-orientated standards in medical research was already complete. The core values had already been laid down in The Nuremberg Code, the first ethics-related document of universal scope aimed explicitly at international recognition (1947) and the Declaration of Helsinki (1964) . These texts established the basic principles of research ethics acknowledging the vulnerability of the patient and the benefits of independent review, under which medical research is now conducted.
Ethical debate during the 1980s and 1990s reached clear consensus that gene therapy raises specific ethical issues as well as public and societal concerns. This debate ultimately led to the establishment of specific guidance and national regulatory systems, which have restricted somatic gene therapy to studies aiming to treat serious, life-threatening or debilitating disorders and have forbidden deliberate alterations to the human germ line.
In 1988, the European Medical Research Council became the first international coalition (Austria, Denmark, Finland, France, The Netherlands, Spain, Sweden, Switzerland, the UK and West Germany) to take a formal stance against germline gene therapy. Germline gene therapy was later also rejected by the Council of Europe in 1991 on the grounds 
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that it would violate the implied right to inherit a genetic pattern that has not been artificially changed. In contrast, UNESCO published relatively liberal guidelines recommending that germline gene therapy should not be illegal.
Against this background, individual nations proposed differing approaches ranging from recommendations that germline gene therapy be indefinitely delayed due to ethical and technical barriers, for example, the USA (1982) through to recommendations that it should be made a criminal offence, for example, Germany (1987) and for voluntary moratoriums, for example, Holland (1989) .
Throughout the world, including America, Canada, Australia and the European Union, gene therapy research is regulated as an experimental therapeutic and subject to general medicines legislation. Many countries have developed mechanisms to provide centralized but nonstatutory advice on gene therapy, particularly in relation to the ethics of this research. Ethical principles have been extended and refined such that they bear relevance to the clinical application of gene therapy. This process has been largely achieved through the operation of specific national ethics committees and advisory boards, for example, the US Recombinant DNA Advisory Committee (RAC), the Australian Gene Therapies Research Advisory Panel (GTRAP) and the UK Gene Therapy Advisory Committee (GTAC). In contrast to countries with central ethics committees such as France and the UK, in the majority of countries ethics are considered at regional or local levels. Importantly, each of these systems provides for central registration of gene therapy trials. Interest in gene therapy research is also growing in the developing world, although with numbers of trials currently in single figures, individual nations have not established mechanisms for central specialized review of gene therapy research. It is unclear at this stage whether these countries will go on to develop models of regulation similar to those applied in the USA, Canada, Europe and Australia ( In September 1999, a teenage volunteer, Jesse Gelsinger, died as a consequence of the administration of an adenoviral gene therapy vector in a study for the inherited condition Ornithine Transcarbamylase Deficiency at the Penn State University. The consequential belated reporting of over 600 serious adverse events (including deaths, although not deemed related to the study product) in other US gene therapy trials led to accusations that a lack of independent oversight was jeopardizing patient safety. Subsequent investigation by the American authorities highlighted noncompliance with the clinical protocol and regulatory requirements. Following an FDA investigation in January 2000, Gelsinger's father sued the research team and subsequently settled out of court for an undisclosed amount. This death galvanized authorities across the globe to re-examine their own policies, specifically in relation to adenoviral gene therapy and has led to an increase in the stringency of safety assessments and patient monitoring in adenoviral trials. For example, in the UK GTAC issued guidance on monitoring to reflect concerns associated with the route of administration, particularly those related to systemic exposure of the vector. It has also heightened awareness of ethical issues around counselling and the process of obtaining informed consent.
The significance of this event rests in the assessment that Jesse's death was the first identified as being related to the study product. This event is also important because, with the introduction of legislation to increase supervision of human gene therapy into the US House of Representatives (February 2000) , it marks the first formal attempt by a legislator to improve public accountability of gene therapy research.
In October and December 2002, the Necker Hospital in Paris announced that the two youngest boys enrolled into a gene therapy study for the treatment of X-SCID had developed a form of leukaemia. 1 The retroviral vector had inserted near the promoter of the protooncogene LMO2. LMO2 encodes a transcription factor whose aberrant expression has been implicated in child- hood T-cell acute lymphoblastic leukaemia. Of the 10 patients treated, nine had shown long-term immune recovery. Other patients treated in France and elsewhere for X-SCID have not developed lympho-prolipherative disorders. These events were not without precedent as the potential for retroviral insertional mutagenesis had previously been well documented in monkeys who had had whole body radiation and went on to develop leukaemias following injection with high titre replication competent retrovirus. Further support for the notion that retroviral vectors can cause oncogenic transformation was published by Li et al (2002) . 2 This preclinical mouse study demonstrated disruption of a gene called Evi1 by a moloney-based vector encoding a truncated form of the LNGFR (low-affinity nerve growth factor receptor) gene. The report led to a suspension of related studies in Germany and a recommendation from GTAC in the UK that the use of such a retroviral vector for the treatment of chronic diseases in children would be unwise. Nevertheless, the risk of similar events in clinical trials employing disabled retroviral vectors was thought to be vanishingly small.
It is still unclear to what extent the risk described by the French leukaemia cases can be translated to other trials. The possible contribution of the gamma-c therapeutic gene itself may have played, the extent to which the primary disease had predisposed to the development of the leukaemia and other issues such as the age of the child at treatment could have had a major bearing on the risk of leukaemia development. Faced with the evidence from the French study, individual nations reached different decisions as to the appropriateness of continuing ex vivo retroviral gene therapy studies. Trials were halted in France and Italy while in the USA all ex vivo retroviral studies were placed on clinical hold by the FDA as a precautionary measure. An earlier ban on ex vivo retroviral studies prompted by the data of Li et al remained in force in Germany.
In the UK, following review of the available evidence after the first reported case of leukaemia in October 2002, GTAC placed a requirement for case-by-case review for each patient enrolled into the UK X-SCID study. Its assessment was to be based on the severity of the disease phenotype, clinical condition of the patient, and the availability and likely outcomes of conventional treatment options for that patient. With ongoing review of the evidence, this restriction was extended to encompass other gene therapy studies involving the modification of haematopoetic stem cells with retroviral vectors to treat inherited disorders (April 2003). 3 By March 2003, trials in the USA that had been earlier subject to a regulatory hold were set to resume following recommendations issued by the RAC and the FDA's Biological Response Modifiers Advisory Committee (BRMAC), who voted 19-1 in favour of allowing these studies to commence. The recommendations stressed the importance of review on a case-by-case basis, but in contrast to the decision reached in the UK, haploidentical stem-cell transplantation was determined preferable to gene therapy.
Both the death of Jesse Gelsinger and the two cases of leukaemia in the French X-SCID study illustrate the principle that side effects of gene therapy will be difficult to predict.
To expect gene therapy to be side effect free is unrealistic and not a restriction imposed on other medical treatments. Mild-side effects are common place in the use of both investigational medicinal products and licensed drugs. Clinical trial design enables the determination of a maximum tolerated dose of a given drug and the level at which its usefulness is limited by toxicity. It has been estimated that there are around 2.2 million severe adverse drug reactions (ADRs) annually in the USA, and that ADRs are the sixth leading cause of death in the USA.
With respect to ADRs in gene therapy, we have gained further insight into the complexity of the provenance of potential side effects, which may relate to the vector, the nature of the therapeutic inserts, the underlying disorders and the clinical and immunological attributes specific to an individual patient. In relation to the process of ethical decision-making, we have learned to accept that differing stances may be validly adopted by individual nations.
The provision of centralized databases of adverse events and the critical evaluation of that data for given vectors across trials could do much to contribute to the development of safe and efficacious vectors. The provision to formalize the sharing ADR data among relevant investigators and regulators may also be beneficial.
New and emerging technologies continue to stimulate ethical debate In utero
For many genetic disorders, where damage is done during foetal development and where prenatal diagnosis has been made, there may be good clinical reasons to intervene in utero. Interventions in the womb are not new; blood transfusions, surgery and the administration of drugs into the developing foetus are established procedures. These procedures did not raise significant public concerns upon their introduction to the clinic. In contrast, the preproposals from Professor French Anderson in 1997 to the RAC, exploring the possibility of applying gene therapy in utero sparked considerable debate and media interest.
Aside from the technical difficulties associated with these procedures, specific ethical questions are raised. These largely relate to the obtaining of informed consent, the balancing of risks and benefits for the mother and foetus, safety, transgenerational risks to the germ line and questions surrounding foetal awareness. The benefit of these debates was to allow an exploration of the scientific, technical and ethical aspects of in utero gene therapy and the issuing of guidance and recommendations in advance of being in receipt of applications to bring these techniques into the clinic. Regulatory statements or guidance were published in the UK and USA in 1998 and 1999, respectively.
At the end of the 1990s, the UK and USA had reached a consensus position where the prospect of in vivo gene therapy in the womb was deemed to be unlikely to be acceptable for the foreseeable future, in view of the safety and ethical difficulties. Five years on, it would be helpful to re-examine the risks and potential benefits of in utero gene therapy in the context of data derived from more recent preclinical studies and advances in the diagnosis and treatment of early onset disorders.
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New viral vectors
A limitation of viral gene therapies for cancer is the inability to target and destroy every cancer cell within a tumour or indeed within a patient. Reliance on the bystander effect is at best a partial solution and conditionally replicating vectors have great potential. The use of such vectors raises questions about the extent to which any proposed vector is to be disabled for replication in normal cells, the degree to which they are targeted to infection of tumour cells and the consequences on third parties of viral shedding. It is still too early to provide prescriptive guidance on the use of such vectors in patients.
Vectors derived from integrating lentiviruses offer many advantages over conventional vectors where longterm, stable gene expression is required in nondividing cells, for example, neurones. However, they also raise safety, ethical and public health anxieties beyond those associated with more conventional gene delivery systems.
These examples illustrate the need for creative vector design to go hand in hand with a presumption towards enhancement efficacy and of safety. Recommendations have, for example, included the use of a human producer cell line to avoid potential problems with endogenous mouse viruses (VL30) and removal of enhancer duplications from the long terminal repeats of MLV-based vectors in order to minimize leukaemogenic potency of the vector.
Two questions arise from the above and other novel developments in vector design. Firstly, how well prepared are we for the new ethical challenges that advances in technology will bring? Secondly, the impact of our national unique histories, cultures, politics and legal systems are exemplified by discordant attitudes to embryo research across the globe.
Commonalties and differences in ethics and regulation have to be identified and discussed
The Director-General of UNESCO has recently called for consideration of the creation of a universal instrument on bioethics. 4 In June 2003, the International Bioethics Committee (UNESCO-IBC) recommended that the proposed instrument be a declaration in order to leave the door open for subsequent protocols.
In particular, the report draws attention to ethical questions arising about the meanings of terms such as 'normal', 'therapy' and 'enhancement'. The IBC suggests that attention needs to be given to questions about balancing risks and benefits, equitable access, the cost of interventions and 'the consequences of the procedures for human evolution'. Clearly, issues related to germline gene therapy and enhancement have not been laid to rest.
Concerns about enhancement are primarily linked to arguments as to the feasibility and desirability of altering traits such as beauty, intelligence and strength. These traits are not monogeneic and considerably influenced by nurture and environment. On closer inspection, the more pertinent concerns centre on the question as to what is normal and what constitutes 'enhancement'. This question may be considered relevant to those trials involving, for example, the delivery of genes to neurones in a way that affects cognitive ability.
New concepts of trial design may apply for gene therapy
Most countries regulate gene therapy under existing laws for conventional drugs; safety, efficacy and quality assessments via the conventional four-phase scheme used for the registration and commercialization of any pharmaceutical product. The European Society for Gene Therapy has suggested that the concepts such as toxicity and efficacy on which phase I/II trials are based should be revised and adapted to reflect the specific nature of gene therapies.
While this suggestion does not argue that gene therapy should not go through the same phases as a new small molecule drug, it does draw attention to special considerations that may apply where the product is an infective agent. Extrapolating virus behaviour in animal models to humans may be misleading; similarly, while the concepts of a threshold dose for efficacy and dose-related toxicity generally hold true for conventional small molecule drugs, they may not apply well to gene therapeutics. Factors such as organ tropism and individuality in immunological response may nullify this presumption. These considerations argue that measurements pertaining to patient immune response should be integrated into decisions on the appropriateness of dose escalation in addition to those relating to clinically manifest ADRs. The Directive unifies standards in drug manufacture in that it requires all investigational medicinal products be produced to full Good Manufacturing Practice, and that the holder of a manufacturing authorization must have permanently and continuously at their disposal at least one (appropriate) qualified person (QP).
The regulatory environment is evolving worldwide Clinical trials regulations in Europe
A central database of all interventional clinical trials of medicinal products in the European Community, EudraCT, has been established and all new clinical trials must now register with this database. The database is confidential and accessible only to competent authorities, the EMEA and the European Commission.
With respect to ethics, an important feature of the Directive is that it allows for a single ethical opinion in each member state (not pan-European opinion). The Directive also draws a distinction with respect to xenotransplantation, somatic cell therapies and gene therapies, allowing extended time lines for ethical approval and the provision for ethics committees to consult a specialist advisory body. The mechanisms for achieving a single ethical opinion and special provisions for gene therapy research will vary. For example, in the UK, the regulations impose a legal obligation to obtain the approval of GTAC as the national research ethics committee for gene therapy human research prior to commencement of any trial. In contrast, the German Commission of Somatic Gene Therapy (CSGT) will advise the local ethics committees with provision for dual submission to CSGT and the REC by the investigator or referral to CSGT by the REC. It is unclear whether those countries lacking a central review board such as GTAC and CSGT will implement the provision for referral to, or central review by a specialist body.
Germline gene therapy is already illegal in several countries, either through provisions of laws regulating use of embryos or because the provisions laid down in the European Convention for Human Rights in BioMedicine have been translated into national legislation. The Clinical Trials Directive once implemented by member states will also render deliberate germline gene therapy illegal.
Genetically Modified Organisms (GMOs) regulations vary from country to country
In Europe, viral vectors are subject to regulation under two directives designed to protect the environment against potentially harmful consequences of GMO release. These directives, on Deliberate Release and Contained Use of GMOs, were largely drafted with GM crops in mind (2001/18/EC & 1998/81/EC). It is argued that such considerations fit pharmaceutical products poorly.
There has been recent acceptance that biological containment is acceptable control in additional to physical and chemical. Interestingly, licensed products will be exempt from either route, as risk assessments will be conducted as part of the medicines licensing procedure with centralized marking authorization via the European Medicines Evaluation Agency (EMEA) subject to Council Regulation EEC/2309/93.
The Directives have not been uniformly interpreted by individual member states and in relation to gene therapy products there are varying approaches to their application. In the UK, for example, all trials to date have been performed in compliance with contained use. In contrast, gene therapies are exempted from the German Gene Technology Law, which translates these directives. The question remains as to whether there is scope for informing interpretation of these directives and the feasibility of developing coordinated guidance on their application in a clinical setting.
Looking to the future -bringing gene therapy into medical practice While early studies were largely restricted to patients who had exhausted conventional treatment options, there has been a gradual shift towards increased acceptance of the appropriateness of gene therapy in less-sick patient groups. Although the Gelsinger case has led to a general reassessment of this trend, there remains a general consensus that early treatment may be desirable in the longer term. This is particularly relevant in the context of tumour burden where the chances of success are likely to be greatest where tumour burden is least. This presumption towards early treatment may also prove necessary if treatments are to be developed for progressive conditions such as cystic fibrosis (CF). In adult CF patients, the lungs are likely to have been damaged by chronic infection and this coupled with the accumulation of mucus may prove a challenge too great to accommodate treatment by gene therapy. In the case of CF, gene therapy targeted at the lungs of children in a clinic trial setting raises specific ethical considerations where risk to minors unable to consent will need to be balanced by a reasonable presumption of benefit.
A related issue is the potential for conducting gene therapy research in healthy volunteer subjects, a practice commonplace in phase I studies of small molecule drugs. In such cases, the potential benefits are limited to the accrual of knowledge, and for the volunteer there can only be the potential for personal risk. Reproductive concerns and the potential for long-term side effects are much greater for the healthy volunteer than for the terminally ill. The risks of the gene therapy may be specific to the underlying disorder and the effects of the vector and/or the therapeutic gene within the context of that disorder. These factors are postulated, for example, to have played a major role in the development of the X-SCID trial leukaemias. Moreover, the majority of pilot or phase I gene therapy studies look for evidence of efficacy (through secondary objectives). It is perhaps for these reasons that the involvement of healthy volunteers to date in gene therapy research has been extremely limited.
As safety data accumulate, there will come a point at which the consensus that gene therapy should be limited to conditions for which current treatments are unavailable or unsatisfactory may be abandoned. This move, coupled with improvements in efficacy, is already leading researchers and regulators to the question of what makes a risk or side effect 'tolerable'. This question is likely to remain unanswered in advance of analysis of longer-term patient monitoring data.
Beyond the research phase there will undoubtedly be challenges associated with the integration of gene therapy into medical practice. These challenges will be practical, for example, the need for appropriate facilities and staff education.
An additional consideration relates to the practicalities of completing a large-scale trial where the target condition is exceedingly rare, as is the case for a number of inherited single-gene disorders that may prove amenable to gene therapy treatment. In these cases, and despite the provision which apply to orphan medicinal products, the challenges of translating this research and bringing forward a licensed drug into standard clinical care are likely to be particularly acute.
There is also likely to be the challenge of deciding where gene therapy should sit in relation to conventional medicines. Trials dealing with rare genetic disorders may not ultimately progress through the four-phase development scheme. Yet at the point where the sole motive for use is that it is the best possible action for an individual patient, these approaches will cross the divide between research and innovative treatment.
The British Government has predicted that gene therapy has the potential to become a 'cornerstone of modern medicine'. 5 Globally, making this prediction a
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